Roche Trontinemab (RG6102) program pivoted post-CLARITY-AD to position Brain Shuttle gantenerumab-derivative as next-generation early-stage AD MAb with reduced ARIA risk profile; explicit positioning vs. lecanemab benchmark.

Evidence span

Roche Trontinemab (RG6102) program pivoted post-CLARITY-AD to position Brain Shuttle gantenerumab-derivative as next-generation early-stage AD MAb with reduced ARIA risk profile; explicit positioning vs. lecanemab benchmark.

Method & conditions

Evidence type

observational

Method

manual state transition

Species

Homo sapiens

Conditions

Roche-Denali Trontinemab Phase Ib (NCT04374253), strategic repositioning 2023+.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required